• The UK’s fastest-growing platform for startups, TechRound, named Cerberus in the top 10 cybersecurity startups and companies
• Cerberus Sentinel is a nationwide provider of cybersecurity consulting and managed services, with offices and resources across the country
• Company believes culture is the foundation of every successful cybersecurity and compliance program

Cerberus Cyber Sentinel (NASDAQ: CISO) was named in the top 10 cybersecurity startups and companies by TechRound, the voice of UK startups and the UK’s fastest-growing platform for startups (https://ibn.fm/cHuEr). Chosen by TechRound’s internal team, the companies were ranked based on “the experience of the team, founders and staff; how the companies have generated success through funding rounds, concept or generating revenue; and the companies’ abilities to overcome issues and help social issues.” Cerberus Sentinel is a “nationwide provider of cybersecurity consulting and managed services, with offices and resources all across the U.S,” reported TechRound. “They specialize in building a security-centric culture for their clients using an education-based approach. To support the ever-expanding list of needs from their clients, they focus on acquiring top cybersecurity talent who specialize in key areas that complement the services offered.” The announcement called out Cerberus Sentinel founder David Jemmett as a leader in the industry. “David has more than 30 years of executive management and technology experience with telecommunications, managed services, and consulting services,” the article noted. “He has specialized expertise in healthcare, HIPAA and governmental regulations, and has been intimately involved in designing, building, revamping, and/or managing networks and data centers worldwide.” The announcement also observed that Jemmett has spoken before the U.S. Congress and Senate subcommittees on Telecommunications and Internet Security. “He has [also] shared his expertise on broadband networking technologies as guest speaker on CBS, CNN, MSNBC and CSPAN,” TechRound stated. As part of CISO’s mission, the company is committed to demystifying and accelerating its clients’ journeys to cyber resilience, empowering organizations to securely grow, operate and innovate (https://ibn.fm/0mHKl). “We believe culture is the foundation of every successful cybersecurity and compliance program,” the company states. This key differentiator sets Cerberus apart from providers who offer their services traditionally, with each solution providing more than just security or compliance improvement. Cerberus designs their services to go beyond delivery to impact an organization’s culture, and the services all work in tandem to achieve this objective. “We are industry leaders who work collaboratively to solve complex cybersecurity challenges, meet strict compliance requirements, and educate your team on the role they play in the cybersecurity and compliance of your organization. This is the Cerberus Sentinel Solution.” For more information, visit the company’s website at www.CerberusSentinel.com. NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

• HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere
• In September 2022, the company announced it was granted a patent for its 12-lead ECG Patch Monitor, opening a pathway to ischemia and arrhythmia detection innovation in ECG Patch products
• In August 2022, the company announced it was seeking FDA approval for its HeartBeam AIMI platform technology used to detect and diagnose heart attacks
• On November 15, 2021, HeartBeam had its IPO on the Nasdaq under ticker symbol ‘BEAT’
• The company’s management team has significant experience in software and medical device product development, with over $1 billion in successful exits over the past 18 months
• HeartBeam was selected as a winner at the annual Cardiovascular Innovations (“CVI”) 2022 Innovation Summit, which recognizes state-of-the-art cardiac technologies

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (“ECG”) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease. In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI(TM) software for approval from the U.S. Food and Drug Administration (“FDA”). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023. HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack. While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products. The company is based in Santa Clara, California. Products HeartBeam’s development portfolio includes two products:

• HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
• HeartBeam AIMIGo(TM), the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being. HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed. Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement. Market Overview Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation. Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (“CMS”), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population. Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (“TAM”) in the U.S. for ECG cardiac arrhythmia monitoring. Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (“CAD”). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD. Management Team Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota. Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom. Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (“CPA”) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University. Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science. For more information, visit the company’s website at www.HeartBeam.com. NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• Power electronics, especially those found in the traction inverters used in EVs, are key to achieving better range, safety, and lifetime; still, improving inverter efficiency has been relatively slow
• Hillcrest stepped up to the challenge of developing a high-efficiency inverter — a new class of clean technology designed to help today’s electric power systems overcome their common limitations
• Hillcrest’s unique inverter architecture can be deployed across different applications, providing opportunities for diversification and de-risking of the company’s revenue streams

Although the popularity of electric vehicles continues to grow amid the ongoing push for energy transition, their design challenges, such as range increase and cost reduction, remain. With aspirations to become an early leader in the electrification of North America and beyond, Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) strives to make an impact where it matters most by offering bold solutions to these key industry challenges. The company develops clean energy technologies intended to unlock electrification efficiencies and enhance the performance of electric systems across various applications, including electric vehicles, and grid-connected renewable energy generation, energy storage and EV charging. While EV technologies have transformed during the past decades, several challenges still impede further proliferation and commercial success. Innovation in this space often means a delicate balancing act between conflicting goals such as range, performance, and cost — which are typically bound by the limitations of power devices. Power electronics, a focus of innovation in electric powertrains, control and convert power and are central to three critical devices: the onboard charger, the traction inverter, and a DC-DC (direct current) converter. Of these three components, the most critical is the traction inverter, which operates at the highest available power and facilitates traction, so any efficiency gains here can increase vehicle range without changing the battery capacity (https://ibn.fm/fSrUD). But although inverters have been around for years, this critical technology has been slower to improve in terms of efficiency. That’s where Hillcrest steps in. Possibly the first company to successfully develop a new class of inverter technology that deploys Zero Voltage Switching (“ZVS”) capabilities. Compared to hard switching, ZVS — also called soft switching — can reduce stress caused during switching and lower switching losses. What differentiates Hillcrest inverter technology is efficiency that surpasses 99%; a design that enables smaller, lighter, and more powerful system capabilities; as well as systems that offer enhanced reliability and performance at lower costs. In addition, Hillcrest’s inverter technology eliminates inverter losses and reduces the thermal management needed across the entire powertrain system (https://ibn.fm/AGaT8). By benefiting from higher operating frequencies at higher voltage, Hillcrest’s solution could overcome historic technology trade-offs and offer improved efficiency, thermal control, and system reliability. This flexible inverter architecture can be deployed across various applications, providing an opportunity for value creation through co-development and collaboration efforts with EV manufacturers and beyond, potentially allowing the company to diversify and de-risk its revenue sources across different sectors and grid-connected energy systems (https://ibn.fm/Jpg9H). With a potential customer base that includes a number of automotive OEMs and tier 1 suppliers and an impeccable reputation across the EU auto, electrical and electronics network, Hillcrest remains focused on balancing short-term revenue maximization with long-term business disruption risk. Leveraging a business model centered around a blend of distinctive, application-specific hardware and software solutions, the company is confident that its new inverter technology will lead to meaningful revenue opportunities in the near future (https://ibn.fm/hfUbS). For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

• Glioblastoma multiforme (“GBM”) is one of the most aggressive, deadly, and treatment-resistant forms of cancer within the brain, with an average life expectancy of 12-18 months and more than 50,000 new cases each year
• The current standard of care for GBM is ineffective for approximately 60% of patients
• Initial Phase 1 trial information for Berubicin (approximately 14 years ago) resulted in one patient surviving cancer-free to present and two experiencing significant tumor reduction of up to 80%

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, recently participated in the H.C. Wainwright 24th Annual Global Investment Conference held on September 12-14, 2022, in New York and online in a hybrid virtual conference. During the event, CEO John Climaco presented the company’s investor presentation and participated in one-on-one investor meetings. An audio recording of Climaco’s presentation is currently available on the company’s News & Events page, through December 11, 2022 (https://ibn.fm/RP8cj). The company’s presentation includes key investor highlights on the efforts being pursued by CNS Pharmaceuticals to develop anti-cancer drug candidates for the treatment of primary and metastatic brain and central nervous system cancer. Berubicin, the company’s lead drug candidate, is a novel anthracycline in an ongoing, potentially pivotal international trial in glioblastoma treatment. The interim analysis data from this potentially pivotal trial is expected in mid-2023. Glioblastoma multiforme (“GBM”) is one of the most aggressive, deadly, and treatment-resistant cancers forming within the brain. Per the company presentation, GBM has an average life expectancy of 12-18 months, with more than 50,000 new cases each year (includes US, France Germany, Italy, Spain, UK, Japan and urban China), accounting for approximately 48% of all primary malignant brain tumors in the US. Unfortunately, the current standard of care for GBM is ineffective for approximately 60% of patients. Anthracyclines are among the most effective anti-cancer treatments. Berubicin was the first to provide scientific data which appears to demonstrate its ability to cross the blood-brain barrier and was designed with a molecular target of topoisomerase II enzymes responsible for cleaving and recombining double-stranded DNA during cellular replication. As tumors are rapidly growing compared to healthy tissues, the anthracycline effects tumor tissues much more than healthy neurons within the brain. The Phase 1 safety trials of Berubicin were conducted around 2006-2007 by Reata Pharmaceuticals, Inc., with one person surviving cancer-free to present and two others showing significant reduction in tumor size by up to 80%. CNS Pharmaceuticals, founded in 2017, entered a collaboration agreement with Reata and has used the initial Phase 1 trial information as the foundation for subsequent trials and to receive FDA Orphan Drug Designation in 2020 and FDA Fast Track Designation in 2021 for Berubicin. The current U.S. Orphan Drug Designation provides CNS Pharmaceuticals with U.S. marketing exclusivity for 7 years post-NDA approval. The company is pursuing Orphan Drug Designation in the EU, which will provide 10 years of protection following European approval. Since the beginning of 2022, CNS Pharmaceuticals has completed pivotal milestones with Berubicin, receiving approval from Switzerland Ethics Committee (“EC”) and Competent Authority (“CA”), France EC, and CA, and Spain EC and CA to open sites. The company’s next steps include pivotal trial expansions into additional countries, expected completion of enrollment, interim analysis/data, and target topline results from the potentially pivotal study. The company offers a strong balance sheet to execute its strategy with cash to progress toward key clinical and regulatory milestones within its development goals. CNS Pharmaceuticals is leveraging its ongoing clinical trial for Berubicin, and the novel anthracycline remains the only competitor to cross the blood-brain barrier to drive value for shareholders. “We are at the point where the finish line is within sight, and that is: ‘Is this drug performing in a clinical setting the way we want it to?’ And if it is, there is nothing to compete with it,” Climaco commented. “We believe this will be an absolute knock-it-out-of-the-park opportunity for neuro-oncology, but we have to prove that carefully, and that’s what we do on a day-to-day basis. That’s how we continue to build that [shareholder] value over time.” For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Correlate just entered into a non-binding letter of intent to acquire Aegis Renewable Energy Inc. in a move that seeks to enhance sales, development, and construction capabilities for the company
• The acquisition also looks to strengthen Correlate’s human resources, equipping it with the necessary skills and expertise to take on the American Northeast market
• It is anticipated to close in Q4 2022 once due diligence is completed, and upon its successful completion, Aegis will become Correlate’s third subsidiary, adding to its growing footprint in the American market
• Aegis will lend Correlate its strategic abilities to capitalize on the growing Northeast renewable energy market, along with its deep regulatory knowledge, project fulfillment, operations, and maintenance capabilities

Correlate Infrastructure Partners (OTCQB: CIPI) just entered into a non-binding letter of intent to acquire Aegis Renewable Energy Inc., a Vermont-based commercial, industrial, and community solar company. Through this acquisition, Correlate looks to bolster its presence in the Northeast while enhancing its sales, development, and construction capabilities (https://ibn.fm/pZ9Er). “This proposed Aegis Renewable Energy acquisition will bolster Correlate’s Northeast presence with a top-notch team that has been successfully executing commercial and community-scale solar energy systems for the past 11 years,” noted Channing Chen, Correlate’s Chief Financial Officer (“CFO”). Aegis has made a name for itself as a leader in the renewable energy space, particularly with its focus on solar project development and engineering, procurement, and construction (“EPC”) services in the eastern United States. The company is also a member of the Amicus Solar Cooperative Network. Aegis will lend Correlate its strategic abilities to capitalize on the growing Northeast renewable energy market, along with its deep regulatory knowledge, project fulfillment, and operations and maintenance capabilities. The acquisition will also strengthen Correlate’s human resources, equipping it with the necessary skills and expertise to take on the Northeast market and make the enterprise more competitive in the region. It comes at an opportune time, with Aegis encountering several offers earlier. According to Nils Behn, Aegis CEO, the company’s focus was finding the best strategic fit to match its growth, culture, diversification, and strength of leadership goals, and Correlate checked off all the boxes. The proposed acquisition is anticipated to close in the fourth quarter of the 2022 financial year, following the completion of all due diligence. Once successful, Aegis will become Correlate’s third subsidiary, after Correlate and Solar Site Design, adding to the growing Correlate footprint in the American market and strengthening its product and service offerings. It will also help accelerate Correlate’s growing quarter-over-quarter results, ultimately increasing its margins and creating value for its shareholders. With the growing potential of the Northeast market, particularly with Vermont’s state government setting goals to meet 90% of its energy needs with renewable sources by 2050, Correlate has positioned itself for growth. It has also set itself on track to being the leading provider of clean energy and grid optimization across North America. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Martin Shen, FingerMotion’s CEO, acknowledged the solid and resilient performance of the company’s Top Up business, noting how the recurring revenue streams from it have created a solid foundation on which to expand its product line
• This expansion has seen the introduction of FingerMotion’s latest offering, a device protection insurance product for mobile phones. The company is looking to hit the milestone of one million devices under its protection plan by early 2023, and 20 million users within three years
• Mr. Shen has lauded the massive onset and adoption of 5G in China as a critical factor for this service’s growth, regarding it as a “tailwind”
• He is confident that the success of this new offering will form an even stronger foundation on which the company can further grow its products and services, grow its revenues and improve its gross margins

While speaking during the signing of a strategic cooperation agreement between China Mobile and Shanghai TengLian JiuJiu Information Communication Technology Co., Ltd (a 99% owned subsidiary), Martin Shen, the Chief Executive Officer (“CEO”) of FingerMotion (NASDAQ: FNGR) acknowledged the resilient performance of the company’s Top Up business. As an evolving technological company with core competencies in mobile payment and recharge platform solutions for the Chinese market, Mr. Shen was keen to note the company’s progress over the years and the role that this business has played in FingerMotion’s growth (https://ibn.fm/FW36e). “One of the other things that we are finding out is that the Top Up business is extremely resilient to any recessionary pressures,” he noted. “The recurring revenue streams that we have created are very predictable and stable, thereby creating a solid foundation on which to expand,” he added. This solid foundation for expansion saw the introduction of FingerMotion’s latest offering, a device protection insurance product for mobile phones. The company looked to tap into an industry rife with potential, yet only limited to broken screen protection. In its market analysis, FingerMotion’s management noted that within three years, the company expects the number of users of its new offering to exceed 20 million, based on ten provinces, municipalities, and other regions. It further noted that by early 2023, the company would achieve full online and provincial offline coverage, hitting the milestone of one million devices under its device protection plan by December. One of the main factors that Mr. Shen noted would aid in the fast adoption of its new service was the 5G adoption within China. “Now with the massive onset of 5G phones, there’s a really large market in China that’s looking to change up their phones for, let’s say, 3G and 4G phones to 5G,” noted Mr. Shen (https://ibn.fm/sGjOJ). He regarded this as a “tailwind,” noting the massive 5G replacement cycle that has already begun and that would push FingerMotion’s service revenues and hardware sales. Through the performance of its Top Up business, along with its other more established offerings, FingerMotion has made a name for itself and formed a solid foundation on which it can grow its products and services. Its device protection plan is a testament to the company’s commitment to constantly delivering value to customers and creating value for its shareholders. Moreover, it indicates a management team in touch with consumers, understands their needs, and is willing to push the company to provide solutions. Going forward, Mr. Shen is confident that as the device protection plan continues to be accessed by more consumers in China, the company’s revenues will increase, adding to gross margin growth for the 2022 financial year. He is also optimistic that this program’s success will further strengthen FingerMotion’s foundation to expand into other sectors and introduce even more product offerings to consumers. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Recent Lightning Network statistics show over 17,000 active nodes with more than 87,000 payment channels facilitating a capacity of over 4,500 BTC worldwide
• LQwD is currently leveraging the Lightning Network with nodes active in the United States, Ireland, India, Germany, Brazil, Hong Kong, Singapore, Sweden, South Korea, South Africa, Bahrain, Indonesia, Italy, Australia, Japan-Osaka, England, Japan, France, and Canada
• LQwD anticipates increasing node coverage to 24 countries by the end of the current quarter

The Lightning Network is a Layer 2 protocol designed to help scale Bitcoin’s base layer. It comprises nodes consisting of payment channels that help facilitate affordable, fast, and more secure payments. As awareness increases, so does the growth of the Lightning Network, with recent statistics showing over 17,000 nodes that exceed 87,000 channels that support a capacity of over 4,500 BTC worldwide (https://ibn.fm/o5Mc4). Nodes in the United States make up more than half of the current capacity with 2,300 BTC currently locked in the Lightning Network, followed by Germany with 355 BTC and Canada with 151 BTC. LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption, is leveraging the Lightning Network in pursuit of expanding the capabilities of bitcoin, with 19 active worldwide nodes on the Lightning Network. The company released its first node, US-West, in November 2021, and the node has since grown to a capacity of over 6 BTC and more than 100 active channels. Other LQwD nodes on the Lightning Network include Ireland, India, Germany, Brazil, Hong Kong, Singapore, Sweden, South Korea, South Africa, Bahrain, Indonesia, Italy, Australia, Japan-Osaka, England, Japan, France, and Canada. The company anticipates expanding its worldwide coverage to include a total of 24 countries by the end of the current quarter. Several countries worldwide have used the Lightning Network to their advantage, opening up payment opportunities that would not have existed otherwise. Last year, El Salvador adopted Bitcoin as a legal tender, using the Lightning Network’s capability to process millions of transactions to facilitate the purchase of everyday goods. The June 2022 Federal Reserve Bank of Cleveland’s paper “Lightning Network: Turning Bitcoin Into Money” describes El Salvador’s bitcoin adoption as a cornerstone moment for the technology and network use by top-named companies, including merchant transactions. (https://ibn.fm/6I7vS). Other countries are making Bitcoin payment more accessible, adding payment options in the cryptocurrency to everyday transactions – like getting a cup of coffee – as described by Paco de la India, who committed to traveling 40 countries on a personal bitcoin standard. His travels are documented on YouTube and Twitter, where he talks about his journeys. “Kenya was one place where I bought a book for bitcoin, got a massage for bitcoin, got food with bitcoin, paid for my guide with bitcoin, and found a pool table, a game of pool that you could play with bitcoin,” de la India explains, adding that he was also able to buy a cup of coffee with Bitcoin in Singapore (https://ibn.fm/foNIk). Kenya and Singapore are not the only countries openly accepting Bitcoin – Guatemala, Costa Rica, Peru, Brazil, Argentina, and South Africa have all recognized the benefits of accepting Lightning Network payments to better the economic standing of their respective countries. As nodes are formed, and channel numbers grow, more countries worldwide are becoming a part of the payment network. According to Markets and Markets, the cryptocurrency market size reached US $1.6 billion in 2021 and is expected to grow at a CAGR of 7.1% through 2026, resulting in a value of US $2.2 billion (https://ibn.fm/3QewN). Transparency, digital ledger technology, and growth opportunities in emerging and developed markets are driving the industry’s growth, bringing new opportunities to the landscape, especially where micropayments are concerned. As a public company, LQwD aims to leverage its position within the industry to enhance the micropayment experience. The company intends to build a strong brand and capture valuable “land” in the highly sought-after digital payments realm. The current plan of execution includes the acquisition of nodes and channels, leveraging the Lightning Network, increasing transaction volumes, and increasing brand awareness as it continues to expand and utilize its own Bitcoin assets. For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• Recent report notes a significant increase in cyber incidents
• CISO is dedicated to “pulling disparate technologies, teams and vendors together to help clients simplify and accelerate their journey to cyber resilience”
• Cerberus Sentinel works closely with clients to integrate compliance and security into an organization-wide culture of cybersecurity

Considering what the government calls “a growing threat to the nation’s power grid,” the U.S. Department of Energy (“DOE”) will provide $45 million in funding to support next-generation cybersecurity research, development and demonstration projects (https://ibn.fm/GiiZZ). That’s good news for companies, including Cerberus Cyber Sentinel (NASDAQ: CISO), who excel in the space, providing essential protection to core U.S. energy infrastructure. “The North American Electric Reliability Corp. in July said that reports of cyber incidents — including vulnerabilities, phishing, malware, denial of service and others — ‘increased significantly’ in 2021,” reported a recent Cybersecurity Dive article (https://ibn.fm/KcVhb). “While reliability was maintained, the organization warned that nation-state adversaries and organized cyber criminals have the ability to disrupt critical infrastructure.” With that in mind, the DOE announced $45 million to “create, accelerate, and test technology that will protect our electric grid from cyber-attacks to seamlessly help deploy clean and cheap energy to Americans,” the statement read. “Cyber threats to American energy systems can shut down critical energy infrastructure and disrupt energy supply, the economy, and the health of American consumers.” The DOE statement continued: “Combined with the additional grid upgrades funded in the Bipartisan Infrastructure Law and the Inflation Reduction Act, the United States will have an opportunity to build greater cyber defenses into our energy sector. Today’s funding will support up to 15 research, development, and demonstration (“RD&D”) projects that will focus on developing new cybersecurity tools and technologies designed to reduce cyber risks for energy delivery infrastructure.” An industry leader in cybersecurity and compliance services — the company was named in a TechRounds list of top-10 cybersecurity companies (https://ibn.fm/3lqQa) — Cerberus Sentinel has established a reputation for its integrated approach to reduce noise and bridge common silos that often limit the effectiveness of cybersecurity programs. The company is dedicated to “pulling disparate technologies, teams and vendors together to help its clients enjoy a simpler and more successful journey to cyber resilience. Since 2019, Cerberus Sentinel has worked to rapidly expand by acquiring world-class cybersecurity and compliance businesses with top-tier talent who utilize the latest technology to create innovative protection solutions.” A firm believer that cybersecurity is a culture rather than a product, Cerberus Sentinel works closely with its clients to integrate compliance and security into an organization-wide culture of cybersecurity. CISO provides a wide range of high-quality offerings, including audit and compliance, security operations center services, security engineering, virtual chief information security officer services, incident response, certified forensics, technical assessments and cybersecurity training. “In contrast to the majority of cybersecurity firms that specialize in a specific technology or service, Cerberus Sentinel seeks to differentiate itself by remaining technology agnostic, focusing on accumulating highly sought-after subject matter experts,” the company stated. “Cerberus Sentinel believes that bringing together a world-class team of technological experts with multifaceted proficiency in the critical aspects of cybersecurity is key to providing technology agnostic solutions to its clients in a business ecosystem that suffers from a chronic lack of highly skilled professionals.” Cerberus Sentinel’s goal is to help organizations better leverage their security investments by creating a culture of security, allowing them to quantify, define and capture a return on investment from information technology and cybersecurity spending. The company’s end-to-end, holistic process covers every aspect of clients’ cybersecurity and compliance requirements to promote greater efficiency and strengthen awareness about the integral role of internal team members in an organization’s cybersecurity culture. For more information, visit the company’s website at www.CerberusSentinel.com. NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

• Cross-border shipping solutions developer Freight Technologies Inc. is a B2B marketplace builder focused on providing the commercial trucking industry with transparent and efficient automation to simplify necessary communications, coordination and paperwork
• Freight Technologies, also known as Fr8Tech, upgraded its brand and ticker symbol earlier this year following its reverse merger with Hudson Capital Inc.
• Amid the upgrade, the company is reporting new record quarterly revenue that grew by 60 percent over the previous quarter and 45 percent YOY
• The company expects improving market conditions as the nation continues to rebound from COVID’s economic effects to drive long-term growth

At the height of the COVID pandemic two years ago, a large number of people found themselves out of work — many because of economic factors that ravaged day-to-day business cultures and others because they apparently decided it was a good time to choose more satisfying work (https://ibn.fm/gXIpx). The commercial trucking industry’s personnel shortages were a major factor in generating supply chain bottleneck frustrations that have further impacted the economy with retail product insecurity, but as vaccines have helped to drive a reopening of the labor market a newly diverse cadre of truckers, including minorities, women and family partners, has taken to the roads (https://ibn.fm/JAs21). The new blood in the trucking industry, as well as the ongoing challenges created by worker shortages, underline the need for using technology to simplify processes and eliminate inefficiencies in the movement along the supply chain. Over-the-road shipping technology innovator Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) has developed a AI-powered marketplace solution for optimizing and automating the supply chain process to help keep trucks moving with minimal obstacles. The company’s Fr8app B2B marketplace is its flagship product in a suite of communications products powered by artificial intelligence (“AI”) and machine learning technology that helps connect shippers with qualified carriers as a real-time broker portal. Freight Technologies is concentrated on cross-border and intra-national shipping within North America’s NAFTA trade area, and its efforts to upgrade its brand and ticker symbol earlier this year have helped establish a new identity that is producing rising revenues. In the company’s Q2 2022 financial report, Fr8Tech noted that quarterly revenue for the period ended June 30 grew 60 percent over the Q1 report and was up 45 percent for the period YOY, establishing a new record for the company. “The growth reflects greater traction in each of our dedicated capacity product, Fr8Fleet, and our U.S. domestic Fr8App services,” Fr8Tech CEO Javier Selgas stated in connection with the report (https://ibn.fm/xnjGf). “Fr8App offers many advantages including time and cost savings that benefit shippers and carriers. Even when macro-economic challenges persist, goods still need to be delivered in a timely and costly manner, and Fr8App makes the whole process easier. As such, we continue to broaden our customer reach.” Selgas stated the company anticipates steady long-term growth, especially as market conditions improve and fuel prices stabilize. Fr8App’s focus on transparency and efficiency is a significant driver in helping smaller carriers, particularly those working to meet Mexico’s tight CFDI 4.0 freight law deadline for companies registered in Mexico’s Tax Administration Service. The legal standard was set to take effect as early as 2021, but industry concerns led to an extension of the deadline to January 2023 (https://ibn.fm/CSRaD). For more information, visit the company’s website at www.Fr8Technologies.com. NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT Corporate Communications IBN (InvestorBrandNetwork) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

Taking place November 2-3, 2022 in Philadelphia, the 3rd Next-Gen MSL Excellence Summit empowers Medical Science Liaisons with all the scientific data tools and customer outreach skills they need to build successful relationships with all stakeholders.  The faculty of industry leaders will help attendees refine their approach to Key Opinion Leaders and clearly, convincingly communicate it with patients throughout the product life cycle. Registering for this event gains you an all-access pass to 3 programs in 1! Attendees can also learn and network in discussions and sessions from the 6th Digital Strategy & Innovation for Medical Affairs Summit or the 2nd Investigator-Initiated Trials Summit. The event is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing b2b events. Important topics of discussion:

• Discuss and analyze career opportunities and better horizons for MSLs
• Strategic planning for onboarding to offer the best experience to newbies
• Ways to successfully collaborate with cross-functional teams
• Learn unique ways of soft skill MSL management
• Innovative strategies for synchronizing medical affairs with clinical development and commercial teams
• Leverage emotional intelligence to engage KOLs, gather insights and relay scientific information
• Most effective ways to achieve success as an MSL
• Predict future trends for the optimum development and success of MSLs
• Discuss the role of MSL in voicing the patient’s opinion in research and development

MSLs need to learn effective presentation techniques in physical and virtual formats. To help with these needs, at this event industry experts will share tips on correct body language, proper conduct and effective communication skills to ensure that the MSLs engage with the audience. Special fireside chats will cover ways to elevate the voice of the patient in R&D. Thought leaders will discuss how trauma-informed languages help in medical education as well as shared decision-making and best practices in patient-centric education. The discussions will involve the robust use of digital technology within the organization’s KOL strategy to optimize field engagement, advance scientific partnerships, and better clinical insights. To learn more, please visit https://ibn.fm/LjmS1.